Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action
The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducing the risk of the development or progression of heart failure. In a landmark trial called Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [EMPA-REG Outcomes], long-term treatment with empagliflozin prevented fatal and nonfatal heart failure events but did not reduce the risk of myocardial infarction or stroke in diabetic patients. Observations: The beneficial effect of SGLT2 inhibitors on heart failure cannot be explained by their actions on glycemic control or as osmotic diuretics. Instead, in the kidneys, SGLT2 functionally interacts with the sodium-hydrogen exchanger, which is responsible for the majority of sodium tubular reuptake following filtration. The activity of sodium-hydrogen exchanger is markedly increased in patients with heart failure and may be responsible for both resistance to diuretics and to endogenous natriuretic peptides. In addition, in the heart, empagliflozin appears to inhibit sodium-hydrogen exchange, which may in turn lead to a reduction in cardiac injury, hypertrophy, fibrosis, remodeling, and systolic dysfunction. Furthermore, the major pathophysiological derangements of heart failure and a preserved ejection fraction may be mitigated by the actions of SGLT2 inhibitors to reduce blood pressure, body weight, and fluid retention as well as to improve renal function. The benefits of spironolactone in patients with heart failure with either a reduced or a preserved ejection fraction may also be attributable to the actions of the drug to inhibit the sodium-hydrogen exchange mechanism. Conclusions and Relevance: The benefits of SGLT2 inhibitors in heart failure may be mediated by the inhibition of sodium-hydrogen exchange rather than the effect on glucose reabsorption. This hypothesis has important implications for the design and analysis of large-scale outcomes trials involving diabetic or nondiabetic patients with chronic heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Self-citationBasal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Pfeffer, M. A., Claggett, B., Assmann, S. F., Boineau, R., Anand, I. S., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., Gordeev, I., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013255 · Cited by 1,065
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Baartscheer, A., Schumacher, C. A., Wüst, R. C. I., Fiolet, J. W. T., Stienen, G. J. M., Coronel, R., & Zuurbier, C. J. (2017) · Diabetologia · doi:10.1007/s00125-016-4134-x · Cited by 661
Vallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507
Lee, T.-M., Chang, N.-C., & Lin, S.-Z. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.035 · Cited by 504
SGLT2 Inhibitors and the Diabetic Kidney
Fioretto, P., Zambon, A., Rossato, M., Busetto, L., & Vettor, R. (2016) · Diabetes Care · doi:10.2337/dcs15-3006 · Cited by 348
Boonman-de Winter, L. J. M., Rutten, F. H., Cramer, M. J. M., Landman, M. J., Liem, A. H., Rutten, G. E. H. M., & Hoes, A. W. (2012) · Diabetologia · doi:10.1007/s00125-012-2579-0 · Cited by 343
Sattar, N., McLaren, J., Kristensen, S. L., Preiss, D., & McMurray, J. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3956-x · Cited by 309
Erdmann, E., Charbonnel, B., Wilcox, R. G., Skene, A. M., Massi-Benedetti, M., Yates, J., Tan, M., Spanheimer, R., Standl, E., Dormandy, J. A., et al. (2007) · Diabetes Care · doi:10.2337/dc07-0717 · Cited by 290
Euglycemic Diabetic Ketoacidosis: A Review
Modi, A., Agrawal, A., & Morgan, F. (2017) · Current Diabetes Reviews · doi:10.2174/1573399812666160421121307 · Cited by 264
Habibi, J., Aroor, A. R., Sowers, J. R., Jia, G., Hayden, M. R., Garro, M., Barron, B., Mayoux, E., Rector, R. S., Whaley-Connell, A., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0489-z · Cited by 262
Sano, M., Takei, M., Shiraishi, Y., & Suzuki, Y. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2760w · Cited by 252
Eaton, C. B., Pettinger, M., Rossouw, J., Martin, L. W., Foraker, R., Quddus, A., Liu, S., Wampler, N. S., Hank Wu, W.-C., Manson, J. E., et al. (2016) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002883 · Cited by 219
Maurer, M. S., King, D. L., El-Khoury Rumbarger, L., Packer, M., & Burkhoff, D. (2005) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2004.10.006 · Cited by 211
Self-citationEngelhardt, S., Hein, L., Keller, U., Klämbt, K., & Lohse, M. J. (2002) · Circulation Research · doi:10.1161/01.res.0000014966.97486.c0 · Cited by 206
Baartscheer, A. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00809-x · Cited by 203
Nakamura, T. Y., Iwata, Y., Arai, Y., Komamura, K., & Wakabayashi, S. (2008) · Circulation Research · doi:10.1161/circresaha.108.175141 · Cited by 186
Sciarretta, S., Palano, F., Tocci, G., Baldini, R., & Volpe, M. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.427 · Cited by 185
Pessoa, T. D., Campos, L. C. G., Carraro-Lacroix, L., Girardi, A. C. C., & Malnic, G. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013060588 · Cited by 184
Na+/H+ exchange inhibition reduces hypertrophy and heart failure after myocardial infarction in rats
Kusumoto, K., Haist, J. V., & Karmazyn, M. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.280.2.h738 · Cited by 161
Na+ transport in the normal and failing heart — Remember the balance
Despa, S. I., & Bers, D. M. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.04.011 · Cited by 158
Spencer, A. G., Labonte, E. D., Rosenbaum, D. P., Plato, C. F., Carreras, C. W., Leadbetter, M. R., Kozuka, K., Kohler, J., Koo-McCoy, S., He, L., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007790 · Cited by 158
Kusaka, H., Koibuchi, N., Hasegawa, Y., Ogawa, H., & Kim-Mitsuyama, S. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0473-7 · Cited by 155
Joubert, M., Jagu, B., Montaigne, D., Marechal, X., Tesse, A., Ayer, A., Dollet, L., Le May, C., Toumaniantz, G., Manrique, A., et al. (2017) · Diabetes · doi:10.2337/db16-0733 · Cited by 151
Baartscheer, A., Schumacher, C. A., VANBORREN, M., Belterman, C. N. W., Coronel, R., Tobias Opthof, A., & Fiolet, J. W. T. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.09.024 · Cited by 129
Voyaki, S. M., Staessen, J. A., Thijs, L., Wang, J. G., Efstratopoulos, A. D., Birkenhäger, W. H., de Leeuw, P. W., Leonetti, G., Nachev, C., Rodicio, J. L., et al. (2001) · Journal of Hypertension · doi:10.1097/00004872-200103000-00020 · Cited by 126
Sarcolemmal Na+/H+ exchanger activity and expression in human ventricular myocardium
Yokoyama, H., Gunasegaram, S., Harding, S. E., & Avkiran, M. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00730-0 · Cited by 124
Weir, M. R., Januszewicz, A., Gilbert, R. E., Vijapurkar, U., Kline, I., Fung, A., & Meininger, G. (2014) · The Journal of Clinical Hypertension · doi:10.1111/jch.12425 · Cited by 120
Boyce, S. W., Bartels, C., Bolli, R., CHAITMAN, B. R., Chen, J. C., Chi, E., Jessel, A., Kereiakes, D. J., Knight, J. L., Thulin, L. I., et al. (2003) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(03)00209-5 · Cited by 112
Karmazyn, M., Liu, Q., Gan, X. T., Brix, B. J., & Fliegel, L. (2003) · Hypertension · doi:10.1161/01.hyp.0000102863.23854.0b · Cited by 108
Heise, T., Jordan, J., Wanner, C., Heer, M. A., Macha, S., Mattheus, M., Lund, S. S., Woerle, H. J., & Broedl, U. C. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.001 · Cited by 96
Darmellah, A., Baetz, D., Prunier, F., Tamareille, S., Rücker‐Martin, C., & Feuvray, D. (2007) · Diabetologia · doi:10.1007/s00125-007-0628-x · Cited by 85
EMPA-REG – the “diuretic hypothesis”
McMurray, J. J. V. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.10.012 · Cited by 83
Aker, S. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.04.014 · Cited by 76
Saad, M. S., Mahmoud, A. N., Elgendy, I. Y., Abu‐Zaid, A., Barakat, A. F., Elgendy, A. Y., Al‐Ani, M. A., Mentias, A. G., Nairooz, R. S., Bavry, A. A., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.181 · Cited by 76
Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule
Ghezzi, C., Yu, A. S., Hirayama, B. A., Kepe, V., Liu, J., Scafoglio, C., Powell, D. R., Huang, S.-C., Satyamurthy, N., Barrio, J. R., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016050510 · Cited by 71
Giusti, V. C. D., Nolly, M. B., Yeves, A. M., Caldiz, C. I., Villa‐Abrille, M. C., de Cingolani, G. E. C., Ennis, I. L., Cingolani, H. E., & Aiello, E. A. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.176024 · Cited by 66
Scheen, A. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.05.006 · Cited by 64
Heise, T., Jordan, J., Wanner, C., Heer, M. A., Macha, S., Mattheus, M., Lund, S. S., Woerle, H. J., & Broedl, U. C. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.08.008 · Cited by 64
Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure
Inoue, B. H., dos SANTOS, L., Pessoa, T. D., Antônio, E. L., Pacheco, B. P. M., Savignano, F. A., Carraro‐Lacroix, L. R., Tucci, P. J. F., Malnic, G., & Girardi, A. C. C. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00127.2011 · Cited by 62
von Lewinski, D., Rainer, P. P., Gasser, R. N. A., Huber, M.-S., Khafaga, M., Wilhelm, B., Haas, T., Mächler, H., Roessl, U., & Pieske, B. M. (2010) · Metabolism · doi:10.1016/j.metabol.2009.10.025 · Cited by 61
Mineralocorticoid Action and Sodium-Hydrogen Exchange: Studies in Experimental Cardiac Fibrosis
Young, M. J., & Funder, J. W. (2003) · Endocrinology · doi:10.1210/en.2003-0039 · Cited by 51
The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects
Vettor, R., Inzucchi, S. E., & Fioretto, P. (2017) · Diabetologia · doi:10.1007/s00125-016-4194-y · Cited by 42
Karagodin, I., Aba-Omer, O., Sparapani, R., & Strande, J. L. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0490-9 · Cited by 34
Na+/H+ exchanger in the regulation of platelet activation and paradoxical effects of cariporide
Chang, H. B., Gao, X., Nepomuceno, R., Hu, S., & Sun, D. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2014.12.023 · Cited by 29
van Brummelen, P., & Schalekamp, M. A. D. H. (1980) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1980.tb09718.x · Cited by 26
Cited by
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Heart Failure With Reduced Ejection Fraction: A Review
Murphy, S. P., Ibrahim, N. E., & Januzzi, J. L. (2020) · JAMA · doi:10.1001/jama.2020.10262 · Cited by 769
Metadata
- Authors
- Packer, M., Anker, S. D., Butler, J., Filippatos, G., & Zannad, F.
- Venue
- JAMA Cardiology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-09-01
- Volume
- 2
- Issue
- 9
- Pages
- 1025
- ISSN
- 2380-6583 (ISSN-L)
- OpenAlex
- W2741979119
- Cited by
- 336
- References
- 58
- FWCI
- 30.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.